Analyst firms · Morgan Stanley · GSK
Morgan Stanley GSK price target and rating history
GSK plc (GSK) · Health Care
Morgan Stanley rates GSK plc (GSK) Equal-Weight with a $44 price target, as of its latest action on Feb 12, 2025. It has published 3 rating actions on GSK since August 2022, including 0 upgrades and 0 downgrades.
- Current rating
- Equal-Weight
- Price target
- $44
- Median target, all firms
- Too few
- Actions on GSK
- 3
Every Morgan Stanley rating on GSK
- Feb 12, 2025
- Jan 23, 2024
- Aug 5, 2022
How other firms rate GSK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Jefferies | Hold | $55.90 | Oct 29, 2026 |
| Wolfe Research | Outperform | $70 | Oct 9, 2026 |
| Berenberg | Buy | Sep 15, 2026 | |
| RBC Capital Markets | Sector Perform | Sep 9, 2026 | |
| Citigroup | Neutral | Jul 24, 2026 | |
| HSBC | Hold | Jul 6, 2026 | |
| Barclays | Underweight | Jan 6, 2026 | |
| BofA Securities | Neutral | Nov 25, 2025 |
Questions about Morgan Stanley and GSK
- What is Morgan Stanley's price target for GSK?
- Morgan Stanley's latest stated price target for GSK plc (GSK) is $44, from its action on Jan 23, 2024.
- What is Morgan Stanley's rating on GSK?
- Morgan Stanley rates GSK Equal-Weight, a neutral rating, as of Feb 12, 2025.
- When did Morgan Stanley last change its view on GSK?
- On Feb 12, 2025, Morgan Stanley starts coverage at Equal-Weight.
More GSK rating histories
All Morgan Stanley ratingsGSK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.